Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue of PA-15-188 Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01, Clinical Trial Optional)

Notice Number: NOT-DA-17-057

Key Dates
Release Date: December 5, 2017

Estimated Publication Date of Announcement:

01/08/2018

First Estimated Application Due Date:

02/05/2018

Earliest Estimated Award Date:

07/03/2018

Earliest Estimated Start Date:

07/03/2018

 

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA), with other NIH Institutes and Centers (ICs), intends to reissue PA-15-188 the Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01, Clinical Trial Optional) seekapplications for research on support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. 

The FOA is expected to be published January 2018 with an expected application due date in February 2018.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details
Research is needed to examine cannabis-related compounds as alternative therapies for pain management. Important in this endeavor is to develop a deeper understanding of the role of natural cannabinoids and endocannabinoids in pain perception, processes, and outcomes.  Research is also needed to determine how to modulate key endocannabinoid receptors, ligands, and enzyme levels in pain conditions.  This funding opportunity announcement (FOA) encourages research project grant (R01) applications that study cannabinoids (phytocannabinoids and synthetic cannabinoids) and the endocannabinoid system to evaluate the therapeutic potential of the endocannabinoid system across a variety of pain conditions.
Funding Information
Estimated Total Funding

 

Expected Number of Awards

 

Estimated Award Ceiling

 

Primary CFDA Numbers

93.279

Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
City or township governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization

Applications are not being solicited at this time.

 

Inquiries

Please direct all inquiries to:
David Thomas, PhD
National Institute on Drug Abuse (NIDA)
301-435-1313
dthomas@nida.nih.gov